Please provide your email address to receive an email when new articles are posted on . CHICAGO — A treatment strategy of torsemide vs. furosemide did not improve long-term clinical outcomes for ...

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, demonstrated consistent efficacy and safety regardless of diuretic type or dose and reduced overall diuretic requirements in patients ...

This study will employ a randomized order, double-blind, repeated measures dose ranging design. This design was chosen in order to generate multiple within-subject serial loop diuretic dose response ...

Diuretic therapy remains a cornerstone in the management of heart failure, targeting intravascular and interstitial volume overload to alleviate symptoms, improve exercise tolerance and reduce ...

BARCELONA, Spain—Patients with heart failure (HF) who are predicted to have a high risk of diuretic resistance tend to fare worse no matter whether they wind up taking furosemide or torsemide, with ...

Semaglutide reduces the need for loop diuretic use and dose, and has positive effects on symptoms, physical limitations, and body weight in patients with heart failure with preserved ejection fraction ...

Dapagliflozin (Farxiga) appears to be no more effective than the "thiazide-like" diuretic metolazone at improving pulmonary congestion and fluid status in patients with acute heart failure (AHF), ...

Finerenone reduced heart failure events and cardiovascular deaths in patients with HFmrEF or HFpEF when used with diuretics. The study found finerenone reduced hypokalemia risk but increased ...

Starting dapagliflozin (Farxiga) early during acute heart failure hospitalization didn't boost decongestion, although it appeared to spare loop diuretic doses and increase diuresis compared with usual ...